Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EAN 2022
CMSC 2022
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Trial Updates
5:28
Using machine learning predictions to design more efficient MS clinical trials
David Li-Bland
• 2 Mar 2022
1:27
SAkura: long-term safety and efficacy of satralizumab for NMOSD
Michael Levy
• 25 Feb 2022
4:50
Biology or poor trial design…What underlies remyelination trial failures in MS?
Gavin Giovannoni
• 1 Mar 2022
1:39
Recent progress and future needs in NMOSD treatment
Michael Levy
• 25 Feb 2022
2:12
Key clinical trials of disease modifying therapies in Parkinson’s disease
Fabrizio Stocchi
• 18 Mar 2022
8:59
Phase II trial of ambroxol as a disease modifying therapy for Parkinson’s disease dementia
Stephen Pasternak
• 16 Mar 2022
1:44
Investigating the impact of at-home training and tDCS on cognitive function in MS
Leigh Charvet
• 26 Feb 2022
0:59
Utilizing tDCS to improving hand dexterity in patients with MS
Leigh Charvet
• 26 Feb 2022
3:57
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS
Gavin Giovannoni
• 1 Mar 2022
2:22
COVID-19 outcomes in patients with relapsing MS receiving cladribine
Gavin Giovannoni
• 1 Mar 2022
4:10
Environmental interactions in multiple sclerosis according to DRB1 hetero-homozygosity
Lars Alfredsson
• 25 Feb 2022
3:32
Factors affecting the risk of relapsing- and progressive-onset multiple sclerosis
Lars Alfredsson
• 25 Feb 2022
1:23
CanProCo: understanding factors related to progression in MS
Jiwon Oh
• 25 Feb 2022
2:22
Long-term safety and efficacy of tolebrutinib for relapsing multiple sclerosis
Jiwon Oh
• 25 Feb 2022
1:09
Ozanimod: long-term safety and efficacy in relapsing MS
Jeffrey Cohen
• 24 Feb 2022
1:32
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD
Michael Levy
• 25 Feb 2022
Previous
1
2
3
4
5
6
7
8
…
14
Next